Richard R. Furman, MD attended medical school at Mount Sinai followed by Internal Medicine Residency at the Hospital of the University of Pennsylvania.  He subsequently attended fellowship in Hematology and Oncology at Weill Cornell Medical College.  Since that time, he has focused on immunologic aspects of CLL and lymphomas, focusing in the laboratory on NF-kappaB and immune impairments in CLL.  Since leaving the lab, Dr. Furman has focused his research on non-chemotherapeutic approaches for the treatment of CLL and lymphomas.  He initially focused on thalidomide and lenalidomide, before wordking on novel monoclonal antibodyies, BCR antagonists, and other small molecule inhibitors.  Dr. Furman has played a key role in the development of idelalisib, ibrutinib, acalabrutinib, zanubrutinib, venetoclax and umbralisib and focuses now on understanding and treating mechansims of resistance.  Dr. Furman is currently the Morton Coleman, MD Distinguished Professor of Medicine at Weill Cornell Medicine / New York Presbyterian Hospital.